Stockreport

CytoDyn Phase 2 study of leronlimab cleared by FDA [Seeking Alpha]

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF Patient enrollment for the study will begin in early 2025. The study will be conducted with Syneos Health. “This milestone reflects the continued positive development [Read more]